Literature DB >> 10893476

Effect of methotrexate on the temporomandibular joint and facial morphology in juvenile rheumatoid arthritis patients.

D O Ince1, A Ince, T L Moore.   

Abstract

Juvenile rheumatoid arthritis is a disease characterized by chronic inflammation in one or more joints; it affects children and adolescents up to 18 years of age. This disease may cause significant skeletal joint destruction, and the temporomandibular joint, like other joints, may become severely affected resulting in aberrant mandibular growth, abnormal dentofacial development, and/or altered orofacial muscle function. Methotrexate is the most common remittive agent used in juvenile rheumatoid arthritis to modify the course of inflammatory destruction of peripheral joints. The purpose of this study was: (1) to evaluate the effect of methotrexate therapy on the prevalence of temporomandibular joint lesions and aberration in craniofacial development in children afflicted with juvenile rheumatoid arthritis; (2) to further examine the relationship between the temporomandibular joint/cephalometric findings and rheumatologic data (ie, age at onset, duration of disease); and (3) to evaluate further pauciarticular- and polyarticular-onset disease in juvenile rheumatoid arthritis and the prevalence of temporomandibular joint lesions and facial dysmorphology. The following information was obtained from 45 patients with juvenile rheumatoid arthritis: (1) routine rheumatologic clinical examination data; (2) anamnestic temporomandibular joint evaluation data; (3) clinical temporomandibular joint examination data; (4) lateral cephalometric measurement data; (5) posteroanterior cephalometric measurement data; and (6) individually corrected axial tomographic data. The results demonstrated the following: (1) radiographic evidence of condylar degeneration was apparent in 63% of all patients with juvenile rheumatoid arthritis with pauciarticular patients showing less temporomandibular involvement than polyarticular patients; (2) polyarticular juvenile rheumatoid arthritis patients receiving methotrexate showed less severe temporomandibular joint involvement than the polyarticular patients not receiving methotrexate; (3) the craniofacial structure was affected to a greater extent in the polyarticular form of the disease; (4) the craniomandibular index scores were significantly greater in the polyarticular group; (5) vertical height asymmetry and chin deviation were noted in more than 50% of the patients; and (6) there was a correlation between the severity of condylar lesions and cephalometric findings (ie, mandibular retroposition, posterior rotation, smaller ramus and mandibular dimensions) and the onset and duration of the disease. In conclusion, under the conditions of this study, methotrexate therapy was effective in minimizing temporomandibular joint destruction and craniofacial dysmorphology in juvenile rheumatoid arthritis patients with the polyarticular form of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893476     DOI: 10.1067/mod.2000.104953

Source DB:  PubMed          Journal:  Am J Orthod Dentofacial Orthop        ISSN: 0889-5406            Impact factor:   2.650


  11 in total

Review 1.  Juvenile idiopathic arthritis-and now?: a systematic literature review of changes in craniofacial morphology.

Authors:  Julia von Bremen; Sabine Ruf
Journal:  J Orofac Orthop       Date:  2012-07-11       Impact factor: 1.938

2.  Dentofacial characteristics of patients with rheumatoid arthritis.

Authors:  Derya Yıldırım; Hakan Türkkahraman; H Hüseyin Yılmaz; Ahmet Yalçın Güngör; Yunus Ugan
Journal:  Clin Oral Investig       Date:  2012-10-11       Impact factor: 3.573

3.  Effectiveness of dexamethasone iontophoresis for temporomandibular joint involvement in juvenile idiopathic arthritis.

Authors:  Rina Mina; Paula Melson; Stephanie Powell; Marepalli Rao; Claas Hinze; Murray Passo; T Brent Graham; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

4.  Effect of methotrexate on the mandibular development of arthritic rabbits.

Authors:  Thomas Michael Präger; Philipp Meyer; Smbat Rafayelyan; Kirsten Minden; Paul-Georg Jost-Brinkmann
Journal:  Eur J Orthod       Date:  2014-12-17       Impact factor: 3.075

5.  Relationship between disease course in the temporomandibular joints and mandibular growth rotation in patients with juvenile idiopathic arthritis followed from childhood to adulthood.

Authors:  Mg Fjeld; Lz Arvidsson; H-J Smith; B Flatø; B Ogaard; Ta Larheim
Journal:  Pediatr Rheumatol Online J       Date:  2010-04-22       Impact factor: 3.054

Review 6.  [Juvenile idiopathic arthritis: the silent killer of pediatric temporomandibular joints].

Authors:  N Tzaribachev; D Weber; M Horger
Journal:  Z Rheumatol       Date:  2010-03       Impact factor: 1.372

7.  The temporomandibular joint in juvenile idiopathic arthritis: frequently used and frequently arthritic.

Authors:  Sarah Ringold; Randy Q Cron
Journal:  Pediatr Rheumatol Online J       Date:  2009-05-29       Impact factor: 3.054

8.  Intra-articular vs. systemic administration of etanercept in antigen-induced arthritis in the temporomandibular joint. Part II: mandibular growth.

Authors:  Peter Stoustrup; Kasper D Kristensen; Annelise Küseler; Thomas K Pedersen; John Gelineck; Troels Herlin
Journal:  Pediatr Rheumatol Online J       Date:  2009-02-06       Impact factor: 3.054

9.  Temporomandibular condylar alterations in juvenile idiopathic arthritis most common in longitudinally severe disease despite medical treatment.

Authors:  Anna-Lena Cedströmer; Margareta Ahlqwist; Anna Andlin-Sobocki; Lillemor Berntson; Britt Hedenberg-Magnusson; Lars Dahlström
Journal:  Pediatr Rheumatol Online J       Date:  2014-09-14       Impact factor: 3.054

Review 10.  Temporomandibular joint arthritis in juvenile idiopathic arthritis, now what?

Authors:  Matthew L Stoll; Chung H Kau; Peter D Waite; Randy Q Cron
Journal:  Pediatr Rheumatol Online J       Date:  2018-04-25       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.